TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03697759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + selfBACK
Description: The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient.
Study: NCT03592537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
Study: NCT02409745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch
Description: local injury to the endometrium by Pipelle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial scratch
Description: local injury to the endometrium by Pipelle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch
Description: local injury to the endometrium by Pipelle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial scratch
Description: local injury to the endometrium by Pipelle
Study: NCT04673747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual correction of the sacroiliac joint
Description: Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
Study: NCT01574638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
Study: NCT04168372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fructose, fructose labeled meal
Description: Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fructose, pyruvate labeled meal
Description: Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fructose, fructose labeled meal
Description: Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fructose, pyruvate labeled meal
Description: Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
Study: NCT03009877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
Study: NCT01084200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol for maintenance
Description: Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane+Propofol
Description: Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
Study: NCT01292694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Oral, single-dose, 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Oral, single-dose, 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, single administration, gelatin capsule filled with microcrystalline cellulose
Study: NCT02347215

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life assessment
Description: Seattle Angina Questionnaire and other questionnaires.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stress imaging
Description: Stress imaging
Study: NCT01579045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: bilateral daily use soft contact lens
Study: NCT02762838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-055
Description: BCD-055 is infliximab biosimilar

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade®
Study: NCT04623879

Intervention type: DRUG
Intervention: Lumacaftor, Ivacaftor Drug Combination
Study: NCT01037595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turmeric
Description: turmeric 500 md tid orally for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 3 time orally for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turmeric
Description: 500 mg tid orally for 8 weeks
Study: NCT03141229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness based stress reduction
Study: NCT02064322

Intervention type: DEVICE
Intervention: SImmetry Implant
Description: The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.
Study: NCT01662921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH
Description: Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH
Description: Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
Study: NCT02764801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast agent (Contrast-enhanced ultrasound)
Description: Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logiq E9 Scanner (Contrast-enhanced ultrasound)
Description: Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
Study: NCT02762838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients will receive methotrexate in a dose from 10 to 25 mg per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: All patients will receive methotrexate in a dose from 10 to 25 mg per week.
Study: NCT02543372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Description: BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
Study: NCT04483492

Intervention type: DRUG
Intervention: Caffeine citrate
Description: diaphragm contractility after administration
Study: NCT03403751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reltecimod 0.5 mg/kg
Description: Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
Study: NCT03944759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plan block
Description: serratus anterior plan block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plan block
Description: serratus anterior plan block
Study: NCT02103959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Slow bolus IV administration of CMX-2043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Slow bolus IV administration of CMX-2043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Slow bolus IV administration of CMX-2043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Slow bolus IV administration of PBS
Study: NCT02140216

Intervention type: BIOLOGICAL
Intervention: No blood transfusion
Description: No blood transfusion

Intervention type: BIOLOGICAL
Intervention: Day 0 blood transfusion
Description: Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.

Intervention type: BIOLOGICAL
Intervention: Day 1 or 2 blood transfusion
Description: Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
Study: NCT00455559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study: NCT03505593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENVUE System
Description: The ENvizion Medical™ ENVUE™ System is designed to aid qualified operators in the placement of the ENvizion Medical™ Enteral Feeding Tube™ into the stomach or small intestine.
Study: NCT03796416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: used at a rate of 25 mcg Q4hours for cervical ripening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: used at a rate of 25 mcg Q4hours for cervical ripening.
Study: NCT02517242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pens Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)
Study: NCT03004170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Administered Coping Effectiveness Training
Study: NCT03188068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral administered with sirolimus
Study: NCT01077739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil (5FU)
Description: standard FOLFOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: standard FOLFOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: standard XELOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: standard XELOX or FOLFOX regimen
Study: NCT04203992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videogame
Description: True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way.
Study: NCT02762838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: All patients will receive folic acid in a dose of 5 mg per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: All patients will receive folic acid in a dose of 5 mg per week.
Study: NCT00152971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 1 - day 2 to completion
Description: low dose regimen taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 1 - day 1
Description: low dose regimen taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 2 - day 2 to completion
Description: high dose regimen taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Dose 2 - day 1
Description: high dose regimen taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 30 mg subcutaneously twice daily
Study: NCT03820323

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC VL and targeted DRM testing.
Description: Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL\>1000 copies/mL) is detected.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SOC VL testing
Description: SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
Study: NCT01058434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT03395834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O3
Description: O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
Study: NCT02576158

Intervention type: PROCEDURE
Intervention: TCT，HPV，colposcopic inspection
Study: NCT03191929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT Intervention
Description: Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Control Arm
Description: Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website.
Study: NCT05983744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 Hz Control
Description: Lower body negative pressure (LBNP) applied to -60 mmHg for 10-min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.1 Hz PPT
Description: Lower body negative pressure (LBNP) applied at a frequency of 0.1 Hz from -30 mmHg to -90 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.05 Hz PPT
Description: Lower body negative pressure (LBNP) applied at a frequency of 0.05 Hz from -30 mmHg to -90 mmHg
Study: NCT00545363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate 150 mg QM orally for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Participants will receive ibandronate 150 mg QM orally for 6 months.
Study: NCT02001974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Reparixin
Description: Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Reparixin
Description: Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Reparixin
Description: Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
Study: NCT00747526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 5 mg
Description: Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 10 mg
Description: Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
Study: NCT02153359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Efficiency Particulate Air Cleaner

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Efficiency Particulate Air Cleaner

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham air cleaner

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham air cleaner
Study: NCT03377868

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic coherence tomography
Description: Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic coherence tomography
Description: Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
Study: NCT03655990

Intervention type: DEVICE
Intervention: Treatment with the JUVORA™ Dental Disc
Description: treatment with the JUVORA™ Dental Disc